16th International HIV Drug Resistance Workshop

Conference Reports for NATAP


16th International HIV Drug Resistance Workshop June 12-16, 2007, Barbados, West Indies

	Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2s (08/23/07) Sensitive Testing Demonstrates a High Prevalence of Transmitted Drug Resistance among Conventionally Genotyped Wildtype HIV-1 Infections (07/09/07) Inferring Virological Response from Genotype: With or without predicted phenotypes? (07/09/07) Intermittent Antiretroviral Prophylaxis with Tenofovir and Emtricitabine (FTC) Protects Macaques Against Repeated Rectal SHIV Exposures (07/05/07) Integrase/CCR5/TMC125 Resistance, New Drugs, GAG, Ultra-Deep Sequencing for Low-Level ART Drug Resistance, Abbreviated TDF/FTC PreP Therapy Effective in Monkeys. Barbados - Report by David Margolis, MD (07/05/07) Biochemical Characterizations and drug sensitivity of the Effect of Mutations Selected in HIV-1 Integrase Gene Associated with Failure to Raltegravir (MK-0518) (07/02/07) Prior Emergence of K103N after Single Dose Nevirapine Predicts Detection of K103N after Exposure to Single Dose Nevirapine in a Subsequent Pregnancy (07/02/07) Highly Potent Protease Inhibitors with Novel Escape Pathways (06/27/07) Genotypic relationships between tipranavir and darunavir resistance in protease inhibitor experienced patients (06/26/07) Resistance and Cross-Resistance to First Generation Integrase Inhibitors: Insights from a Phase 2 Study of Elvitegravir (GS-9137) (06/25/07) Roche NNRTI Potent Against TMC125 & TMC278 Resistance In Vitro (06/25/07) New Roche CCR5 Potent Against Maraviroc Resistance In Vitro (06/25/07) Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2 (06/25/07) A Structural Basis for Resistance to PL-100, a New (unboosted) Protease Inhibitor for PI Resistance (06/25/07) Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis of Protocol 005, a Phase 2 Study in Patients with Triple-Class Resistant HIV-1 Infection (06/22/07) In vivo Emergence of HIV-1 Resistance to the CCR5 Antagonist Vicriviroc: Findings from ACTG 5211 (06/21/07) Mapping of Vicriviroc Resistance Mutations in HIV-1 gp120 Generated by in vitro Selection of a Primary HIV-1 Isolate in PM-1 Cells (06/21/07) Protease Gene Mutations in a Trial Comparing First Line LPV/r Monotherapy to LPV/r + AZT/3TC (MONARK Trial) (06/20/07) CXCR4-using Virus Detected in Patients Receiving Maraviroc in the Phase 3 studies MOTIVATE 1 and 2 Originates from a Pre-existing Minority of CXCR4-using Virus (06/20/07) An Open, Randomized, 2-Way Crossover Study to Investigate the Effect of Darunavir/Ritonavir on the Pharmacokinetics of Maraviroc in Healthy Subjects (06/20/07) Resistance Profile after Viral Rebound on Atazanavir-Containing Therapy: Focus on Protease Inhibitor Naive Subjects in the IMPACT Study (BMS AI424-128) (06/19/07) Antiviral Efficacy and Emergent PI Substitutions in Treatment-Naive Subjects Receiving Atazanavir +/- Ritonavir-Based HAART in Subtype B and Non-Type B HIV-1 Infection(06/19/07) Prediction of Reyataz Clinical Response Rate by Phenotypic Fold Change Using Kaplan-Meier Estimate in the AI424-045 Study(06/19/07) Low NNRTI Levels Before Drug Breaks Predict Resistance - Written by Mark Mascolini - (06/15/07) New Method Spots Hidden Mutations That Predict Failure - Written by Mark Mascolini - (06/15/07) Pluses and Minuses of First-Line Lopinavir Versus Efavirenz: drug resistance in ACTG 5142 - Written by Mark Mascolini - (06/15/07) Lower Barrier to Resistance with Lopinavir/Ritonavir Monotherapy - Written by Mark Mascolini - (06/15/07) Transmitted Resistance Worse in North American Than in Europe - Written by Mark Mascolini - (06/15/07) Online Coreceptor Algorithm Predictors Won't Work in Clinic - Written by Mark Mascolini - (06/15/07) Ultra Deep Sequencing Identifies HIV Drug Resistance At Early Stage (06/15/07) Sensitive Genotype Testing Finds Twice As Many Mutations Compared to Standard Genotyping and Study Reports This is associated with Virologic Failure (06/15/07) Impact of high baseline resistance to approved protease inhibitors (and fosamprenavir) on darunavir/r virologic response in treatment-experienced patients in POWER 1, 2 and 3 (06/15/07) HIV Seems Not to "Switch" Coreceptors in Maraviroc Failure, But Is From X4 Reservoir - Written by Mark Mascolini - (06/15/07) Mutations Don't Explain Vicriviroc Failure in ACTG Trial - Written by Mark Mascolini - (06/15/07) Maraviroc Analysis Highlights Difficulties in Defining Resistance - Written by Mark Mascolini - (06/15/07) Mutations Outside V3 Loop May Further Resistance to CCR5 Drugs - Written by Mark Mascolini - (06/15/07) How Dangerous Is CCR5 Antagonist Failure? - Written by Mark Mascolini - (06/15/07) R1206, a representative of a new class of potent diphenylether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species - (06/15/07) In vitro resistance profile of the human immunodeficiency virus type 1 to two new HIV-1 protease inhibitors: CRS-074 and CRS-075 - (06/15/07) New NNRTI IDX12899 anti-HIV-1 activity and resistance profile is superior to efavirenz - (06/15/07) Cross-Resistance Between Integrase Inhibitors Looks Likely - Written by Mark Mascolini - (06/14/07) Thirteen NNRTI Mutations Linked to Etravirine Resistance - Written by Mark Mascolini - (06/14/07) Covert Mutations in Both Recently and Chronically Infected People - Written by Mark Mascolini - (06/14/07) Transmitted Resistance in Rural US (north Carolina) Matches That in Cities - Written by Mark Mascolini - (06/14/07) New HIV Drugs at Drug Resistance Workshop 6/12 Barbados - (06/13/07)